Webinar Friday Lecture Series
(open to the Tri-I community)
Friday, September 17, 2021
Kevan Shokat, Ph.D.
Professor
Department of Cellular and Molecular Pharmacology and Pharmaceutical Chemistry
University of California, San Francisco
Discovering and Deploying Chemical Strategies to Drug KRAS: The Formerly Undruggable Oncogene
Recommended Readings:
Empirical Articles
Nnadi, Chimno I.; Jenkins, Meredith L.; Gentile, Daniel R. et al. (2018). Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange. JOURNAL OF CHEMICAL INFORMATION AND MODELING. 58(2): 464-471
Gentile, Daniel R.; Rathinaswamy, Manoj K.; Jenkins, Meredith L. et al. (2017). Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States. CELL CHEMICAL BIOLOGY. 24(12): 1455 -1466.e14
Novotny, Chris J.; Hamilton, Gregory L.; McCormick, Frank; Shokat, Kevan M. (2017). Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. ACS CHEMICAL BIOLOGY. 12(7): 1956-1962
McGregor, Lynn M.; Jenkins, Meredith L.; Kerwin, Caitlin et al. (2017). Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. BIOCHEMISTRY. 56 (25): 3178-3183
Review Paper
Dang, CV; Reddy, EP; Shokat, KM and et. (2017). Drugging the ‘undruggable’ cancer targets. NATURE REVIEWS CANCER. 17(8): 502-508